Related Experiment Video
Updated: Aug 31, 2025
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
New Indication for Dupilumab.
1Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch : diane.aschenbrenner@gmail.com .
Dupilumab (Dupixent) is now approved for treating eosinophilic esophagitis in patients 12 years and older weighing at least 40 kg. This marks the first FDA-approved medication for this chronic gastrointestinal condition.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Eosinophilic esophagitis (EoE) is a chronic, immune-mediated esophageal disease.
- EoE is characterized by esophageal eosinophil-driven inflammation.
- Current treatment options for EoE are limited and often focus on symptom management or dietary elimination.
Purpose of the Study:
- To report the FDA approval of Dupilumab (Dupixent) for the treatment of eosinophilic esophagitis (EoE).
Main Methods:
- This section is not applicable as the abstract reports an FDA approval.
Main Results:
- Dupilumab (Dupixent) has received FDA approval for the treatment of eosinophilic esophagitis.
- The approval applies to adult and pediatric patients aged 12 years and older who weigh at least 40 kilograms.
- This signifies a significant advancement in targeted therapy for EoE.
Conclusions:
- Dupilumab represents the first FDA-approved pharmacologic treatment for eosinophilic esophagitis.
- This approval offers a new therapeutic option for patients with this debilitating condition.
More Related Videos
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023